research Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
Search
for
Sort by
Research
480-510 / 1000+ results 
research Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
Reporter characteristics affect detection of hair loss from cancer therapy.
research Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions
Low-dose oral minoxidil can cause serious side effects like heart issues, so use the lowest effective dose.
research Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor
Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
research Inconsistent platelet-rich plasma product from devices cleared by the US FDA: A retrospective review of clinic data
PRP treatments for hair loss need standard protocols to be reliable.
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.
research Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
research Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
New technologies replicate human skin for testing without animals.
research The Effects of Lower vs Higher Cell Number of Platelet-Rich Plasma (PRP) on Hair Density and Diameter in Androgenetic Alopecia (AGA): A Randomized, Double-Blinded, Placebo, Parallel-Group Half-Scalp IRB-Approved Study.
Higher cell number PRP improves hair density and diameter more than lower cell number PRP.
research Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
Topical minoxidil may cause more side effects than currently listed, needing updated safety information.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
research Finasteride Use: Evaluation of Depression and Suicide Risk
Finasteride use may increase depression and suicide risk, especially at 1 mg, so monitoring is advised.
research Exosomes in Cosmetic Dermatology: A Review of Benefits and Challenges
Exosomes could improve skin and hair treatments, but more research and regulation are needed.
research Public Interest in JAK Inhibitors for Alopecia Areata: A Google Trend Analysis (Preprint)
Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.
research Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia
Oral minoxidil is an effective alternative for hair loss but may cause more unwanted hair growth.
research Global online interest in finasteride sexual side effects
Public interest in finasteride's sexual side effects has significantly increased.
research How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects
Finasteride, a hair loss drug, has unaddressed sexual side effects due to the manufacturer's inadequate safety measures and lack of additional studies.
research Off-label prescriptions: patient safety first
Off-label drug use can be risky and requires careful consideration to ensure patient safety.
research Alopecia – New building blocks
New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
research Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy
Effective delivery systems are crucial for siRNA hair loss treatments to work better.
research Regulatory, Ethical, and Safety Considerations of Exosome‐Based Therapies in Dermatology
Exosome-based therapies in dermatology show promise but face challenges in standardization, regulation, and safety.
research What to Look for in Red Light Therapy: A Product Guide Backed by Science
Choose FDA-cleared red light therapy devices and follow guidelines for safe use.
research Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
research Reporting on Adverse Clinical Events
The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.
research Alopecia Areata: An Updated Review for 2023
Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
research The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
research Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
research Exploring the historical stigma of spironolactone use in breast cancer survivors with alopecia
Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.